5-Amino-1MQ as a potential obesity treatment via NAD+ modulation
Abstract Glutamate is the primary excitatory neurotransmitter in mammalian brain
References: National Institute for Health and Care Excellence (NICE)
The treatment, which was previously indicated only for symptomatic children 3 years of age and older with late infantile CLN2 disease, also known as Batten disease, can now be given to diagnosed children of all ages, regardless of whether they are symptomatic or presymptomatic
Several commenters provided suggestions related to improving the TiC and NSA regulations, the 340B program, transparency of Medicare and Medicare Advantage rates, and extending the HPT requirements to other providers
These can be found specifically listed on our individual pricing pages